us-cms-medicare-manuals-pub-100-04-clm104c17crosswalk•100-04 Medicare Claims Processing Manual: Chapter 17 Crosswalk
100-04 Medicare Claims Processing Manual: Chapter 17 Crosswalk
us-cms-medicare-manuals-pub-100-04-clm104c17crosswalk100-04 Medicare Claims Processing Manual: Chapter 17 CrosswalkGuidance
Medicare Claims Processing Manual Chapter 17 - Drugs and Biologicals Crosswalk New Chap New Sect Int. Pub. 13 Carrier Pub 14. SNF Pub 12 Other Source Description 17 10 B3-2049, B3-5201 A-00-36, B-01-10, B-01-38, AB-01-16, A-02-129, AB-02-174, AB-03-014 Payment Rules for Drugs and Biologicals 17 20 B3-5202, R1799B3 AB-02-075, PRM 2711.2 B. 2 Payment Allowance Limit for Drugs and Biologicals 17 20.1 AB-02-075, B-03-059, AB-03-047, PRM 2711.2 B. 2 Single Drug Pricer (SDP) 17 20.2 B3-5202.1 AB-02-075, PRM 2711.2 B. 2 Calculation of the AWP 17 20.3 B3-5202.1 AB-02-075, PRM 2711.2 B.2 Detailed Procedures for Determining AWPs and the Drug Payment Allowance Limits 17 20.3.1 Background 17 20.3.2 AB-02-075, PRM 2711.2 B. 2 Review of Sources for Medicare Covered Drugs and Biologicals 17 20.3.3 AB-02-075, PRM 2711.2 B. 2 Use of Generics
New Chap New Sect Int. Pub. 13 Carrier Pub 14. SNF Pub 12 Other Source Description 17 20.3.4 AB-02-075, PRM 2711.2 B. 2 Find the Strength and Dosage 17 20.3.5 AB-02-075, PRM 2711.2 B. 2 Restrictions 17 20.3.6 AB-02-075, PRM 2711.2 B. 2 Inherent Reasonableness for Drugs and Biologicals 17 20.3.7 B3-5202.2 Injection Services 17 20.3.8 B3-5202.3 Injections Furnished to ESRD Beneficiaries 17 30 B3-5202.1 AB-02-075, PRM 2711.2 B. 2 Carrier Distribution of Limit Amounts 17 40 AB-02-075, PRM 2711.2 B. 2 Discarded Drugs and Biologicals 17 50 B3-5247 PM B-01-15 Assignment Required for Drugs and Biologicals 17 60 PM B-01-02 DMEPOS Suppliers Require a License to Dispense Drugs 17 60.1 B3-4118 Prescription Drugs Billed by Suppliers Not Licensed to Dispense Them 17 70 Staff developed-No Xref Claims Processing Requirements - General 17 70.1 B-03-041 Billing Drugs Electronically - NCPDP 17 70.1.1 B-03-057 Reporting Modifiers in the Compound Drug Segment 17 70.1.2 B-03-057 Coordination of Benefits (COB)
New Chap New Sect Int. Pub. 13 Carrier Pub 14. SNF Pub 12 Other Source Description 17 70.1.3 B-03-057 Inbound NCPDP Claim 17 80 Title+Xref-Not in manual Claims Processing for Special Drug Categories 17 80.1 A3-3660.13 SNF 536.1 Oral Cancer Drugs 17 80.1.1 A3-3660.13 SNF 536.1 HCPCS Service Coding for Oral Cancer Drugs 17 80.1.2 A3-3660.13 SNF 536.1 HCPCS and NDC Reporting for Prodrugs 17 80.1.3 A3-3660.13 SNF 536.1 Other Claims Processing Issues for Oral Cancer Drug 17 80.1.4 A3-3660.13 SNF 536.1 MSN/ANSI X12N Message Codes for Oral Cancer Drug Denials 17 80.2 A3-3660.15 B3-4460 PM A-98-5 Oral Anti-Emetic Drugs Used as Full Replacement for Intravenous Anti-Emetic Drugs as Part of a Cancer Chemotherapeutic Regimen 17 80.2.1 A3-3660.15 B3-4460 PM A-98-5 HCPCS Codes for Oral Anti-Emetic Drugs 17 80.2.2 A3-3660.15 B3-4460 PM A-98-5 Claims Processing Jurisdiction for Oral Anti-Emetic Drugs 17 80.2.3 A3-3660.15 B3-4460 PM A-98-5 MSN /ANSI X12N Denial Messages for Anti-Emetic Drugs 17 80.3 B3-4471 PM AB-01-10 Billing for Immunosuppressive Drugs 17 80.3.1 A3-3660.8 Requirements for Billing FI for Immunosuppressive Drugs
New Chap New Sect Int. Pub. 13 Carrier Pub 14. SNF Pub 12 Other Source Description 17 80.3.2 MSN/Remittance Messages for Immunosuppressive Drugs 17 80.4 B3-5245 PM AB-00-117, AB-03-014 Billing for Hemophilia Clotting Factors 17 80.5 A3-3660.11, A3-3660.12 SNF 536.1 PM AB-02-72 Self-Administered Drugs 17 90 Title-No Xref Claims Processing Rules for Hospital Outpatient Billing and Payment 17 90.1 PM-A-00-42, A-00-61, A-01-50 Blood/Blood Products and Drugs Classified in Separate APCs for Hospital Outpatients 17 90.2 A-02-026 Changes to Pass-Through Drugs and Biologicals Final Rule 17 90.2.1 PM A-02-026, §IX.A HCPCS Codes Replacements 17 90.2.2 PM-A-02-026 §IX.B Codes Not Recognized for Medicare Under the Hospital OPPS 17 90.2.3 PM-A-02-026 §IX.C Additional Drugs Eligible for Pass-Through Payments 17 90.2.4 PM-A-02-026 §IX.D Changes to Payment Rates and Co-Pay From the March 1, 2002 OPPS Final Rule 17 90.2.5 PM-A-02-026 §IX.E Additional Corrections 17 90.2.6 PM-A-02-026 §IX.F Additional Billing and Reporting Information Related to Pass-Through Drugs Effective April 1, 200
New Chap New Sect Int. Pub. 13 Carrier Pub 14. SNF Pub 12 Other Source Description 17 90.2.7 PM-A-02-026 §IX.G Typographical Errors from the March 1, 2002, OPPS Final Rule 17 90.2.8 PM-A-02-026 §IX.H Correction to 2003 HCPCS Code Books 17 90.2.9 PM-A-02-026 §X Pro-Rata Reduction in Drug and Device Pass-Through Payments
Wondering how this text applies to your situation?
Free consultation, no commitment
Describe your situation. Our team will contact you by email about your consultation.
Continue your research in ChatGPT or Claude
Connect Omnilex to search the legal corpus from your AI assistant.